BioVie Inc. Net Fee Amt
BioVie Inc. (BIVI) had Net Fee Amt of $0 as of 2026-08-14, per its S-1/A filed 2026-08-14.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-08-14
- 2026-08-14: Net Fee Amt $0.00.
- 2026-07-31: Net Fee Amt $3.45K.
- 2026-07-17: Net Fee Amt $6.91K.
- 2026-06-11: Net Fee Amt $41.43K.
| Period end | Net Fee Amt |
|---|---|
| 2026-08-14 | $0.00 S-1/A · filed 2026-08-14 |
| 2026-07-31 | $3.45K S-1/A · filed 2026-07-31 |
| 2026-07-17 | $6.91K S-1 · filed 2026-07-17 |
| 2026-06-11 | $41.43K S-3 · filed 2026-06-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aspire Biopharma Holdings, Inc. (ASBP) | United States | $0.012B | -0.60 |
| ADIAL PHARMACEUTICALS, INC. (ADIL) | United States | $0.012B | |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |
| Tempest Therapeutics, Inc. (TPST) | United States | $0.013B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |